ARGX supply chain intelligence for argenx SE: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
argenx SE (ARGX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ABBV | AbbVie Inc. | 80% | Reciprocal relationship from ABBV graph: Reciprocal relationship from ARGX graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from ARGX graph: We currently have collaborative res… |
| ABBV | AbbVie Inc. | 80% | We currently have collaborative research relationships with various pharmaceutical companies such as AbbVie |
| ZAI-LAB | ZAI-LAB | 80% | We currently have collaborative research relationships with various pharmaceutical companies such as AbbVie, Zai Lab |
| IMVT | Immunovant, Inc. | 72% | Reciprocal relationship from IMVT graph: Reciprocal relationship from ARGX graph: Reciprocal relationship from IMVT graph: Reciprocal relationship from ARGX graph: Reciprocal relationship from IMVT g… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| VYVGART | VYVGART | 90% | We also have distribution agreements in place with several distribution partners for VYVGART |
| AGMB | AGMB | 72% | rrently generating product net sales on a straight-line basis over the estimated useful life, being the longer of the current patent protection life of the acquired R&D and patent protection life of … |
| AGMB | AGMB | 72% | Reciprocal relationship from AGMB graph: Reciprocal relationship from ARGX graph: rrently generating product net sales on a straight-line basis over the estimated useful life, being the longer of the… |
| AZN | AstraZeneca PLC | 72% | more than 26 years of experience in quality assurance within the pharmaceutical industry. Most recently, Ms. Wilk served as senior director, head of medical, regulatory & clinical quality assurance a… |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from ARGX graph: Reciprocal relationship from AZN graph: Reciprocal relationship from ARGX graph: Reciprocal relationship from AZN grap… |
| IMVT | Immunovant, Inc. | 72% | Reciprocal relationship from IMVT graph: gulated, unapproved and off-label treatments. Even if a biosimilar product is less effective than our product candidates, a less effective biosimilar may be m… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from ARGX graph: lement our business strategy is subject to numerous risks that you should be aware of before making an investment deci… |
| JNJ | Johnson & Johnson | 72% | lement our business strategy is subject to numerous risks that you should be aware of before making an investment decision. These risks are described more fully below. These risks include, among othe… |
| MS-PE | Morgan Stanley | 72% | Reciprocal relationship from MS-PE graph: Reciprocal relationship from ARGX graph: Reciprocal relationship from MS-PE graph: Reciprocal relationship from ARGX graph: Reciprocal relationship from MS-P… |
| MS-PK | Morgan Stanley | 72% | estors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting tho… |
| NVSEF | Novartis AG | 72% | lement our business strategy is subject to numerous risks that you should be aware of before making an investment decision. These risks are described more fully below. These risks include, among othe… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from ARGX graph: lement our business strategy is subject to numerous risks that you should be aware of before making an investment de… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ARGX-DEBT | Debt stack $47.2M | 90% | Market cache reports total debt of $47.2M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| ARGX-OWNER-AVORO-CAPITAL-ADVISORS-LLC | Avoro Capital Advisors LLC | 95% | 13F/ownership overlay lists Avoro Capital Advisors LLC; shares held 1,990,000; value $1.56T; as of 2026-03-31. |
| ARGX-OWNER-FMR-LLC | FMR LLC | 95% | 13F/ownership overlay lists FMR LLC; shares held 4,991,034; value $3.64T; as of 2026-03-31. |
| ARGX-OWNER-PRICE-T-ROWE-ASSOCIATES-INC-MD | PRICE T ROWE ASSOCIATES INC /MD/ | 95% | 13F/ownership overlay lists PRICE T ROWE ASSOCIATES INC /MD/; shares held 3,374,955; value $2.5B; as of 2026-03-31. |
| ARGX-OWNER-JANUS-HENDERSON-GROUP-PLC | JANUS HENDERSON GROUP PLC | 95% | 13F/ownership overlay lists JANUS HENDERSON GROUP PLC; shares held 5,083,464; ownership 8.21%; value $3.70T; as of 2026-03-31. |
| ARGX-OWNER-MORGAN-STANLEY | MORGAN STANLEY | 95% | 13F/ownership overlay lists MORGAN STANLEY; shares held 1,514,669; value $1.17T; as of 2026-03-31. |
| ARGX-OWNER-RTW-INVESTMENTS-LP | RTW INVESTMENTS, LP | 95% | 13F/ownership overlay lists RTW INVESTMENTS, LP; shares held 709,446; value $518.1B; as of 2026-03-31. |
| ARGX-OWNER-WELLINGTON-MANAGEMENT-GROUP-LLP | WELLINGTON MANAGEMENT GROUP LLP | 95% | 13F/ownership overlay lists WELLINGTON MANAGEMENT GROUP LLP; shares held 1,021,457; value $745.9B; as of 2026-03-31. |
| ARGX-OWNER-BLACKROCK-INC | BlackRock, Inc. | 95% | 13F/ownership overlay lists BlackRock, Inc.; shares held 808,337; value $590.3B; as of 2026-03-31. |
| ARGX-OWNER-ARTISAN-PARTNERS-LIMITED-PARTNERSHIP | Artisan Partners Limited Partnership | 95% | 13F/ownership overlay lists Artisan Partners Limited Partnership; shares held 1,467,982; value $1.07T; as of 2026-03-31. |
| ARGX-OWNER-CAPITAL-WORLD-INVESTORS | Capital World Investors | 95% | 13F/ownership overlay lists Capital World Investors; shares held 2,256,216; value $1.65T; as of 2026-03-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| BNRG | Brenmiller Energy Ltd | 100.00 | 2 | |
| SNNUF | Smith & Nephew plc | 100.00 | 2 | |
| AGMB | AgomAb Therapeutics NV | 100.00 | 1 | ['customer'] |
| BNR | Burning Rock Biotech Limited | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 1 | ['customer'] |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| CCCC | C4 Therapeutics, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CSTE | Caesarstone Ltd. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| DEO | Diageo plc | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| ALC | Alcon Inc. | 100.00 | 2 |